ArticleJournal of asthma and allergy2026
Persistence and Reasons for Discontinuation of Subcutaneous Immunotherapy in Children with Dust Mite Allergy: A Real-World Cohort from Hangzhou, China.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the present state of adherence to subcutaneous specific immunotherapy (SCIT) in children sensitized to dust mites, explore the factors contributing to the cessation of SCIT in this demographic, and provide scientific evidence aimed at improving compliance and efficacy of SCIT in pediatric patients. Methods: A retrospective analysis was conducted on clinical data of pediatric patients who received treatment at our desensitization center between January 2017 and December 2023. These children exhibited sensitivity to dust mites and were diagnosed with allergic asthma, allergic rhinitis, or other allergic diseases, subsequently undergoing SCIT therapy. The fulfillment of the SCIT regimen was evaluated, and the factors contributing to treatment cessation were analyzed. Results: A total of 680 children were included in the study. Of these, 424 children (62.35%) successfully completed the entire treatment regimen (total course ≥3 years), whereas 256 children (37.65%) chose to discontinue the treatment prematurely (total course <3 years). The reasons for the cessation of SCIT, ranked from most to least common, included efficacy issues (54.69%), drug intolerance (18.75%), family-related factors (10.94%), the repercussions of the COVID-19 pandemic (6.64%), influence from other diseases (6.25%) and various other reasons. The primary reason for discontinuation within the first month was family factors (46.15%), while within six months, it was drug intolerance (40.82%), and after 6 months, efficacy issues (68.04%) became the leading cause. Conclusion: The uncertain efficacy and intolerance to the medication predominantly hinder compliance with SCIT in children, while family factors serve as the main reason for discontinuation within the first month. By enhancing parental comprehension and awareness of SCIT, standardizing operational protocols, and promptly addressing any adverse reactions, compliance with SCIT could be significantly improved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.